Evidence map›Paper›PMID 40993371›Full record

ArticleNature cardiovascular research2025

Cardiac adaptation to endurance exercise training requires suppression of GDF15 via PGC-1α.

Sumeet A Khetarpal, Haobo Li, Tevis Vitale, James Rhee, Saketh Challa, Claire Castro, Steffen Pabel, Yizhi Sun, Jing Liu, Dina Bogoslavski and 26 more

Abstract read
In one paragraph

Article in Nature cardiovascular research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Impact of endurance training on mitochondrial HFrontiers in molecular biosciences · 2025
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors.

Sumeet A KhetarpalCorrigan Minehan Heart Center and Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA.
Haobo LiDepartment of Anesthesia, Critical Care, and Pain Medicine, Harvard Medical School, Massachusetts General Hospital, and the Massachusetts General Research Institute, Boston, MA, USA.
Tevis VitaleDepartment of Cancer Biology, Dana Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-0479-128X
James RheeCorrigan Minehan Heart Center and Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0002-2181-4957
Saketh ChallaCorrigan Minehan Heart Center and Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA.
Claire CastroCorrigan Minehan Heart Center and Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0002-6309-1689
Steffen PabelCenter for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0009-0000-1121-4889
Yizhi SunDepartment of Cancer Biology, Dana Farber Cancer Institute, Boston, MA, USA.
Jing LiuCardioVascular Institute, Beth Israel Deaconess Medical Center, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7962-3096
Dina BogoslavskiDepartment of Cancer Biology, Dana Farber Cancer Institute, Boston, MA, USA.
Ariana Vargas-CastilloDepartment of Cancer Biology, Dana Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-3239-6022
Amanda L SmythersDepartment of Cancer Biology, Dana Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-1552-6705
Katherine A BlackmoreDepartment of Cancer Biology, Dana Farber Cancer Institute, Boston, MA, USA.
Louisa GrauvogelDepartment of Cancer Biology, Dana Farber Cancer Institute, Boston, MA, USA.
Melanie J MittenbühlerDepartment of Cancer Biology, Dana Farber Cancer Institute, Boston, MA, USA.
Melin J KhandekarDepartment of Cancer Biology, Dana Farber Cancer Institute, Boston, MA, USA.
Casie CurtinCardioVascular Institute, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Jose Max Narvaez-PalizaCardioVascular Institute, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Chunyan WangDepartment of Anesthesia, Critical Care, and Pain Medicine, Harvard Medical School, Massachusetts General Hospital, and the Massachusetts General Research Institute, Boston, MA, USA.
Nicholas E HoustisCorrigan Minehan Heart Center and Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA.
Hans-Georg SprengerDepartment of Cancer Biology, Dana Farber Cancer Institute, Boston, MA, USA.
Sean J JurgensCorrigan Minehan Heart Center and Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA.
Kiran J BiddingerCorrigan Minehan Heart Center and Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA.
Alexandra KuznetsovCorrigan Minehan Heart Center and Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA.
Rebecca FreemanCorrigan Minehan Heart Center and Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA.
Patrick T EllinorCorrigan Minehan Heart Center and Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0002-2067-0533
Matthias NahrendorfCenter for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-4021-1887
Joao A PauloDepartment of Cell Biology, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-4291-413X
Steven P GygiDepartment of Cell Biology, Harvard Medical School, Boston, MA, USA.
Phillip A DumesicDepartment of Cancer Biology, Dana Farber Cancer Institute, Boston, MA, USA.
Aarti AsnaniCardioVascular Institute, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Krishna G AragamCorrigan Minehan Heart Center and Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA.
Pere PuigserverDepartment of Cancer Biology, Dana Farber Cancer Institute, Boston, MA, USA.
Jason D RohCorrigan Minehan Heart Center and Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0002-6999-6868
Bruce M SpiegelmanDepartment of Cancer Biology, Dana Farber Cancer Institute, Boston, MA, USA. bruce_spiegelman@dfci.harvard.edu.ORCID http://orcid.org/0000-0002-7658-4802
Anthony RosenzweigStanley and Judith Frankel Institute for Heart and Brain Health, University of Michigan, Ann Arbor, MI, USA. anthros@med.umich.edu.ORCID http://orcid.org/0000-0001-6387-0386

Funding

Understanding the Cardiac Benefits of Exercise at the Cellular and Molecular LevelR35HL155318 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ANTHONY ROSENZWEIG · 2021 to 2026
$5.4M
PGC1alpha Pathway: Novel Intracellular and Extracellular MediatorsR01DK119117 · NIDDK · DANA-FARBER CANCER INST · PI BRUCE M. SPIEGELMAN · 2019 to 2026
$4.9M
Hemopexin as an Early Biomarker of Anthracycline Cardiac ToxicityR01HL163172 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Aarti Asnani · 2022 to 2026
$3.2M
Role of Activin Type II receptor signaling in age-related heart failureR01AG061034 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ROSENZWEIG, ANTHONY · 2019 to 2023
$3.0M
Placental Senescence in Peripartum CardiomyopathyR01HL170058 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI JASON DAVID ROH · 2023 to 2026
$1.9M
METTL3 in Cardiac Benefits of Exercise in DiabetesR01HL171201 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI Haobo Li · 2024 to 2026
$1.8M
Activin type II receptor activity in age-related frailty and heart failureK76AG064328 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI ROH, JASON DAVID · 2019 to 2022
$972k
The Role of Family with Sequence Similarity 3D (FAM3D) in Cardioprotection and Inflammation after Myocardial InfarctionK08HL140200 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI RHEE, JAMES · 2019 to 2023
$864k
A Long Noncoding RNA SALTe Links Heart Failure to Alzheimer's DiseaseR21AG077040 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI LI, HAOBO · 2022 to 2022
$446k
Discovery of Heart-Derived Myokines Mediating the Response to Exercise Stress Via PGC-1aK08HL177169 · NHLBI · UNIVERSITY OF VIRGINIA · PI Sumeet Khetarpal · 2025 to 2026
$286k
American Heart Association (American Heart Association, Inc.) 20CDA35310184American Heart Association (American Heart Association, Inc.) 24SCEFIA1253853Damon Runyon Cancer Research Foundation (Cancer Research Fund of the Damon Runyon-Walter Winchell Foundation) DRG 120-17Deutsche Forschungsgemeinschaft (German Research Foundation) 461079553NHLBI NIH HHS K08 HL177169NHLBI NIH HHS R01 HL163172NHLBI NIH HHS R01 HL170058NHLBI NIH HHS R01 HL171201NHLBI NIH HHS R35 HL155318NIA NIH HHS K76 AG064328NIA NIH HHS R01 AG061034NIDDK NIH HHS R01 DK119117U.S. Department of Health & Human Services | National Institutes of Health (NIH) 1T32GM145407U.S. Department of Health & Human Services | National Institutes of Health (NIH) DK125722U.S. Department of Health & Human Services | National Institutes of Health (NIH) HL145019U.S. Department of Health & Human Services | National Institutes of Health (NIH) K08HL140200U.S. Department of Health & Human Services | National Institutes of Health (NIH) K76AG064328U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01HL170058U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01HL171201U.S. Department of Health & Human Services | National Institutes of Health (NIH) R21AG077040
6 · The paper itself

Abstract

Endurance exercise promotes adaptive growth and improved function of myocytes, which is supported by increased mitochondrial activity. In skeletal muscle, these benefits are in part transcriptionally coordinated by peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α). The importance of PGC-1α to exercise-induced adaptations in the heart has been unclear. Here we show that deleting PGC-1α specifically in cardiomyocytes prevents the expected benefits from exercise training and instead leads to heart failure after just 6 weeks of training. Consistent with this, in humans, rare genetic variants in PPARGC1A, which encodes PGC-1α, are associated with increased risk of heart failure. In this model, we identify growth differentiation factor 15 (GDF15) as a key heart-secreted mediator that contributes to this dysfunction. Blocking cardiac Gdf15 expression improves cardiac performance and exercise capacity in these mice. Finally, in human heart tissue, lower cardiomyocyte PPARGC1A expression is associated with higher GDF15 expression and reduced cardiomyocyte density. These findings uncover a crucial role for cardiomyocyte PGC-1α in enabling healthy cardiac adaptation to exercise in part through suppression of GDF15.

Indexed as

Endurance TrainingGrowth Differentiation Factor 15Heart FailureMyocytes, CardiacPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaPhysical Conditioning, AnimalPhysical EnduranceAdaptation, PhysiologicalAnimalsDisease Models, AnimalExercise ToleranceHumansMaleMiceMice, Inbred C57BLMice, KnockoutGDF15 protein, humanGdf15 protein, mouseGrowth Differentiation Factor 15Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaPPARGC1A protein, humanPpargc1a protein, mouse

Identifiers

PMID40993371
PMCPMC13158892

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.